Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT07548190
Active, not recruiting Observational

Bidirectional Cohort Study of a Prognosis Model for Acute-on-chronic Liver Failure

NCT07548190 · tracked via the Priya Life Science China tracker
Sponsor
The Second Affiliated Hospital of Chongqing Medical University
Phase
Observational
Started
2018-01-01
Last updated
2026-04-23

Condition(s) studied

Liver Failure

Study summary

This study constitutes a bidirectional cohort investigation. By collating laboratory parameters and clinical data-including plasma and peripheral blood mononuclear cell (PBMC) analyses-from patients with acute-on-chronic liver failure, it aims to provide a reference framework for predicting prognosis and the occurrence of complications.

Eligibility

Sex
ALL
Min age
18 Years
Max age
85 Years
Healthy volunteers
No
Inclusion Criteria: •Clinical diagnosis of Hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) Exclusion Criteria: * age \< 18 years * extrahepatic organ failure unrelated to ACLF * active malignancy * co-infection with other hepatitis viruses or human immunodeficiency virus (HIV) * prior liver transplantation * use of immunosuppressants within 6 months before enrollment * unclear history of antiviral therapy

Primary outcome measure(s)

  • Primary endpoint was all-cause mortality at days 28, 90, 180, and 360. — Days 28, 90, 180, and 360

Trial sites (1)

FacilityCityRegionStatus
Department of Infectious Diseases, Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, The Second Affiliated Hospital, Chongqing Medical University Chongqing China

More The Second Affiliated Hospital of Chongqing Medical University trials in China

Exploring the Optimal Concentration of Lidocaine Test Dose for Labor Analgesia Active, not recruiting
A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (A) Recruiting
Underdilated-stent Technique Improves Post-TIPS Encephalopathy Recruiting
Establishment and Evaluation of Prenatal Prevention and Treatment Strategy for NARDS Recruiting
Application of 4DCT-Based Pulmonary Ventilation Imaging in Lung Cancer Radiotherapy Active, not recruiting

Other trials for the same condition

A Study on Relationship Between Resected Normal Liver Parenchymal Volume（RNLV）and Post-Hepatectomy Liver Failure (PHLF) Recruiting
Registry Study for Optimal Management of Liver Failure in the Chinese Population Recruiting
The Safety ,Tolerability and Efficacy Study of HepaCure in Chinese Subjects with Acute-On-Chronic Liver Failure Recruiting
Fecal Microbiota Transplantation for Liver Failure Recruiting
Safety and Effectiveness of Mesenchymal Stem Cells in Blood Purification for the Treatment of Liver Failure Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07548190 on ClinicalTrials.gov ↗ ← All trials in China